Abilita Bio

Abilita Bio

Biotechnology Industry


Abilita Bio, Inc. was founded in June 2014 and is an innovation-driven biotechnology company focused on enabling discovery and development of drugs targeting challenging membrane proteins, including G Protein-Coupled Receptors (GPCRs) through the application of our Enabled Membrane Proteins (EMPs™) technology platform. Abilita Bio is privately held and owns all the rights to the EMP™ technology and has established several global collaborations around the EMP™ platform, including a multi-target proof of concept agreement with an undisclosed global Pharmaceutical Company.


Social links: